M Elaine Stauble1, Andrew W Moore1, Loralie J Langman2, Mark V Boswell3, Richard Baumgartner4, Suzanne McGee1, Jonathan Metry1, Saeed A Jortani5. 1. Dept. of Obstetrics and Gynecology, University of Louisville School of Medicine, Louisville, USA. 2. Dept. of Lab Medicine and Pathology, Mayo Clinic, Rochester, USA. 3. Dept. of Anesthesiology and Perioperative Medicine, University of Louisville School of Medicine, Louisville, USA. 4. Dept. of Epidemiology and Population Health, University of Louisville, Louisville, USA. 5. Dept. of Pathology and Laboratory Medicine, University of Louisville School of Medicine, Louisville, USA. Electronic address: sjortani@louisville.edu.
Abstract
BACKGROUND: Genetic variations in enzymes that produce active metabolites from pro-drugs are well known. Such variability could account for some of the clinically observed differences in analgesia and side effects seen in postoperative patients. Using genotyping and quantitation of serum concentrations of hydrocodone and its metabolites, we sought to demonstrate the clinical effects of the metabolites of hydrocodone on pain relief. The objective of the current study was to determine whether CYP2D6 genotype and serum hydromorphone levels account for some of the variability in pain relief seen with hydrocodone in a cohort of women post-Cesarean section. METHODS: In 156 post-Cesarean section patients who received hydrocodone, we assessed serum opioid concentrations and CYP2D6 genotypes. Blood samples were collected at that time for genotyping and determination of concentrations of hydrocodone and metabolites by LC-MS/MS. Multivariate analysis was used to determine the relationship between CYP2D6 genotypes, pain relief, side effects, and serum concentrations of hydrocodone and hydromorphone. RESULTS: The CYP2D6 genotyping results indicated that 60% of subjects were extensive, 30% intermediate, 3% poor, and 7% ultra-rapid metabolizers. In the poor metabolizers, the mean plasma hydromorphone concentration was 8-fold lower when compared to that of ultra-rapid metabolizers. Hydromorphone, and not hydrocodone concentrations correlated with pain relief. CONCLUSIONS: This study shows that hydromorphone is generated at substantially different rates, dependent on CYP2D6 genotype. Pain relief correlated with plasma concentrations of hydromorphone, and not with hydrocodone. This suggests that pain relief will vary with CYP2D6 genotype. Inability to metabolize hydrocodone to hydromorphone as seen in the poor metabolizers should alert the clinician to consider alternative medications for managing pain postoperatively.
BACKGROUND: Genetic variations in enzymes that produce active metabolites from pro-drugs are well known. Such variability could account for some of the clinically observed differences in analgesia and side effects seen in postoperative patients. Using genotyping and quantitation of serum concentrations of hydrocodone and its metabolites, we sought to demonstrate the clinical effects of the metabolites of hydrocodone on pain relief. The objective of the current study was to determine whether CYP2D6 genotype and serum hydromorphone levels account for some of the variability in pain relief seen with hydrocodone in a cohort of women post-Cesarean section. METHODS: In 156 post-Cesarean section patients who received hydrocodone, we assessed serum opioid concentrations and CYP2D6 genotypes. Blood samples were collected at that time for genotyping and determination of concentrations of hydrocodone and metabolites by LC-MS/MS. Multivariate analysis was used to determine the relationship between CYP2D6 genotypes, pain relief, side effects, and serum concentrations of hydrocodone and hydromorphone. RESULTS: The CYP2D6 genotyping results indicated that 60% of subjects were extensive, 30% intermediate, 3% poor, and 7% ultra-rapid metabolizers. In the poor metabolizers, the mean plasma hydromorphone concentration was 8-fold lower when compared to that of ultra-rapid metabolizers. Hydromorphone, and not hydrocodone concentrations correlated with pain relief. CONCLUSIONS: This study shows that hydromorphone is generated at substantially different rates, dependent on CYP2D6 genotype. Pain relief correlated with plasma concentrations of hydromorphone, and not with hydrocodone. This suggests that pain relief will vary with CYP2D6 genotype. Inability to metabolize hydrocodone to hydromorphone as seen in the poor metabolizers should alert the clinician to consider alternative medications for managing pain postoperatively.
Authors: Elyse M Cornett; Michelle A Carroll Turpin; Allison Pinner; Pankaj Thakur; Tamizh Selvan Gnana Sekaran; Harish Siddaiah; Jasmine Rivas; Anna Yates; G Jason Huang; Anitha Senthil; Narjeet Khurmi; Jenna L Miller; Cain W Stark; Richard D Urman; Alan David Kaye Journal: Curr Oncol Rep Date: 2020-02-06 Impact factor: 5.075
Authors: Larisa H Cavallari; Emily Cicali; Kristin Wiisanen; Roger B Fillingim; Hrishikesh Chakraborty; Rachel A Myers; Kathryn V Blake; Bolanle Asiyanbola; Jordan F Baye; Wesley H Bronson; Kelsey J Cook; Erica N Elwood; Chancellor F Gray; Yan Gong; Lindsay Hines; Joseph Kannry; Natalie Kucher; Sheryl Lynch; Khoa A Nguyen; Aniwaa Owusu Obeng; Victoria M Pratt; Hernan A Prieto; Michelle Ramos; Azita Sadeghpour; Rajbir Singh; Marc Rosenman; Petr Starostik; Cameron D Thomas; Emma Tillman; Paul R Dexter; Carol R Horowitz; Lori A Orlando; Josh F Peterson; Todd C Skaar; Sara L Van Driest; Simona Volpi; Deepak Voora; Hari K Parvataneni; Julie A Johnson Journal: Clin Transl Sci Date: 2022-08-04 Impact factor: 4.438
Authors: E Paylor Sachtleben; Kelsey Rooney; Hannah Haddad; Victoria L Lassiegne; Megan Boudreaux; Elyse M Cornett; Alan D Kaye Journal: Methods Mol Biol Date: 2022
Authors: Kelly E Dunn; Elise M Weerts; Andrew S Huhn; Jennifer R Schroeder; David Andrew Tompkins; George E Bigelow; Eric C Strain Journal: Addict Biol Date: 2018-10-08 Impact factor: 4.280
Authors: Natalie Reizine; Keith Danahey; Emily Schierer; Ping Liu; Merisa Middlestadt; Jenna Ludwig; Tien M Truong; Xander M R van Wijk; Kiang-Teck J Yeo; Monica Malec; Mark J Ratain; Peter H O'Donnell Journal: Oncologist Date: 2021-09-19
Authors: Kristine R Crews; Andrew A Monte; Rachel Huddart; Kelly E Caudle; Evan D Kharasch; Andrea Gaedigk; Henry M Dunnenberger; J Steven Leeder; John T Callaghan; Caroline Flora Samer; Teri E Klein; Cyrine E Haidar; Sara L Van Driest; Gualberto Ruano; Katrin Sangkuhl; Larisa H Cavallari; Daniel J Müller; Cynthia A Prows; Mohamed Nagy; Andrew A Somogyi; Todd C Skaar Journal: Clin Pharmacol Ther Date: 2021-02-09 Impact factor: 6.903